Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cannabinoids decrease the th17 inflammatory autoimmune phenotype.
Translocator Protein 18 kDa (TSPO) Expression in Multiple Sclerosis Patients.
Treatment of Acute Relapses in Multiple Sclerosis.
Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis.
Treatment of chronic inflammatory polyneuropathy may improve associated hearing loss: A case report and a review of the literature.
Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale.
Building an RNA Sequencing Transcriptome of the Central Nervous System.
Improved determination of the myelin water fraction in human brain using magnetic resonance imaging through Bayesian analysis of mcDESPOT.
Effect of Boswellia papyrifera on cognitive impairment in multiple sclerosis.
A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort.
Neuroimaging and cognition using functional near infrared spectroscopy (fNIRS) in multiple sclerosis.
Tau protein concentrations in the cerebrospinal fluid of children with acute disseminated encephalomyelitis.
Coordinated control of oligodendrocyte development by extrinsic and intrinsic signaling cues.
Amyloid fibril formation and chaperone-like activity of peptides from alphaA-crystallin.
Multiple Sclerosis: Risk Factors and Their Interactions.
Predictors of driving in individuals with relapsing-remitting multiple sclerosis.
Current and emerging therapies in multiple sclerosis: a systematic review.
Does HLA Class II Haplotype play a role in Adult Acute Disseminated Encephalomyelitis? Preliminary Findings from a Southern Italy hospital-based study.
A Group Kickboxing Program for Improving Balance, Mobility, and Quality of Life in Individuals With Multiple Sclerosis: A Pilot Study.
Does natalizumab therapy worsen neuromyelitis optica?
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.
Multiple sclerosis: TNF receptor 1 gene variant could explain failure of TNF-blocking drugs in multiple sclerosis.
MS risk genes are transcriptionally regulated in CSF leukocytes at relapse.
A new therapeutic target for the treatment of multiple sclerosis.
[The neurodegenerative process in multiple sclerosis and the possible neuroprotective effect of treatment with Β-interferon 1a (avonex).]

Pages